FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056521911> ?p ?o ?g. }

• W2056521911 abstract "Background : Panobinostat (LBH589), a potent inhibitor of histone deacetylases (HDACs), has demonstrated single-agent activity and synergistic effects when administered in combination with trastuzumab or docetaxel in HER2-positive breast cancer xenografts. Methods : This multicenter study is enrolling patients with metastatic breast cancer (mBC) who have progressed on or within 6 months of trastuzumab-based therapy. Patients receive panobinostat either intravenously (i.v.) (Day 1+8 every 3 weeks) or orally (three times per week, continuously) in combination with trastuzumab 2 mg/kg weekly. Phase Ib of the study evaluates the maximum tolerated dose (MTD) for each formulation, three i.v. dose cohorts (10, 15 and 20 mg/m 2 ) and four oral dose cohorts (15, 20, 30 and 40 mg) are planned. Once the MTDs are established, Phase IIa of the study will assess the efficacy of these doses. The pharmacokinetic (PK) profile is also being determined. Results : In this ongoing trial, 33 patients have received treatment. At baseline these patients had a median age of 52 y (33–65). All breast cancers were HER2-positive and 16 (48%) were ER and PR negative. Lung (45%), liver (33%) and the central nervous system (21%) were the most common sites of metastatic disease. Most patients had received prior taxanes and/or anthracyclines. For the i.v. arm, the 10 mg/m 2 (n=7) and 15 mg/m 2 (n=7) cohorts completed with no dose-limiting toxicity (DLT), while two out of six patients experienced DLTs in the 20 mg/m 2 cohort. One patient experienced Grade (G) 4 thrombocytopenia, and one patient had G4 nausea, vomiting and diarrhea. The 20 mg/m 2 cohort is currently being expanded to a total of 12 patients to confirm the MTD. For the oral arm, one of six patients experienced a DLT in the 15 mg cohort (uncomplicated G4 thrombocytopenia) and two of eight patients experienced DLTs in the 20 mg cohort. One patient had G3 unstable angina and G3 thrombocytopenia, and the second patient experienced G3 thrombocytopenia and G3 anorexia. The 20 mg cohort has been expanded to 12 patients. Overall the most frequent adverse events reported included gastrointestinal events of nausea, vomiting and diarrhea, and hematologic events of thrombocytopenia and neutropenia. To date, no clinically significant ECG changes have been observed from the 820 ECGs performed. Two patients experienced tumor reduction of 29% (one patient each in the i.v. 10 mg/m 2 and oral 20 mg cohorts); both patients had liver metastasis. Eight of the 25 patients (32%) with tumor measurements had a best response of stable disease, across all cohorts. Five of these patients received over 18 weeks of treatment with the combination. Conclusions : These preliminary results demonstrate that the combination of panobinostat and trastuzumab is well tolerated and shows promising activity. Additional patient safety, efficacy and PK data will be presented. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6101." @default.
• W2056521911 created "2016-06-24" @default.
• W2056521911 creator A5039478541 @default.
• W2056521911 creator A5047771337 @default.
• W2056521911 creator A5049662208 @default.
• W2056521911 creator A5065272343 @default.
• W2056521911 creator A5071553983 @default.
• W2056521911 creator A5075055655 @default.
• W2056521911 creator A5075612639 @default.
• W2056521911 date "2009-12-15" @default.
• W2056521911 modified "2023-09-26" @default.
• W2056521911 title "Phase I Trial of Panobinostat (LBH589) in Combination with Trastuzumab in Pretreated HER2-Positive Metastatic Breast Cancer (mBC): Preliminary Safety, Efficacy and Pharmacokinetic Results." @default.
• W2056521911 doi "https://doi.org/10.1158/0008-5472.sabcs-09-6101" @default.
• W2056521911 hasPublicationYear "2009" @default.
• W2056521911 type Work @default.
• W2056521911 sameAs 2056521911 @default.
• W2056521911 citedByCount "6" @default.
• W2056521911 countsByYear W20565219112012 @default.
• W2056521911 countsByYear W20565219112014 @default.
• W2056521911 countsByYear W20565219112019 @default.
• W2056521911 crossrefType "proceedings-article" @default.
• W2056521911 hasAuthorship W2056521911A5039478541 @default.
• W2056521911 hasAuthorship W2056521911A5047771337 @default.
• W2056521911 hasAuthorship W2056521911A5049662208 @default.
• W2056521911 hasAuthorship W2056521911A5065272343 @default.
• W2056521911 hasAuthorship W2056521911A5071553983 @default.
• W2056521911 hasAuthorship W2056521911A5075055655 @default.
• W2056521911 hasAuthorship W2056521911A5075612639 @default.
• W2056521911 hasConcept C104317684 @default.
• W2056521911 hasConcept C112705442 @default.
• W2056521911 hasConcept C121608353 @default.
• W2056521911 hasConcept C126322002 @default.
• W2056521911 hasConcept C143998085 @default.
• W2056521911 hasConcept C185592680 @default.
• W2056521911 hasConcept C2775930923 @default.
• W2056521911 hasConcept C2778305200 @default.
• W2056521911 hasConcept C2779786085 @default.
• W2056521911 hasConcept C2780225316 @default.
• W2056521911 hasConcept C2781190966 @default.
• W2056521911 hasConcept C530470458 @default.
• W2056521911 hasConcept C55493867 @default.
• W2056521911 hasConcept C64927066 @default.
• W2056521911 hasConcept C71924100 @default.
• W2056521911 hasConcept C98274493 @default.
• W2056521911 hasConceptScore W2056521911C104317684 @default.
• W2056521911 hasConceptScore W2056521911C112705442 @default.
• W2056521911 hasConceptScore W2056521911C121608353 @default.
• W2056521911 hasConceptScore W2056521911C126322002 @default.
• W2056521911 hasConceptScore W2056521911C143998085 @default.
• W2056521911 hasConceptScore W2056521911C185592680 @default.
• W2056521911 hasConceptScore W2056521911C2775930923 @default.
• W2056521911 hasConceptScore W2056521911C2778305200 @default.
• W2056521911 hasConceptScore W2056521911C2779786085 @default.
• W2056521911 hasConceptScore W2056521911C2780225316 @default.
• W2056521911 hasConceptScore W2056521911C2781190966 @default.
• W2056521911 hasConceptScore W2056521911C530470458 @default.
• W2056521911 hasConceptScore W2056521911C55493867 @default.
• W2056521911 hasConceptScore W2056521911C64927066 @default.
• W2056521911 hasConceptScore W2056521911C71924100 @default.
• W2056521911 hasConceptScore W2056521911C98274493 @default.
• W2056521911 hasLocation W20565219111 @default.
• W2056521911 hasOpenAccess W2056521911 @default.
• W2056521911 hasPrimaryLocation W20565219111 @default.
• W2056521911 hasRelatedWork W1960984881 @default.
• W2056521911 isParatext "false" @default.
• W2056521911 isRetracted "false" @default.
• W2056521911 magId "2056521911" @default.
• W2056521911 workType "article" @default.